Published in Br J Cancer on January 01, 1975
Prognostic value of peripheral lymphocyte count in hormone therapy of advanced breast cancer. Br J Cancer (1976) 0.85
Variation in natural killer activity in peripheral blood during the menstrual cycle. Br Med J (Clin Res Ed) (1985) 0.84
Endocrine function and immunity. Br Med J (Clin Res Ed) (1981) 0.75
Thymic proliferative response during different physiological states: a comparative study. J Sci Res Med Sci (2000) 0.75
Nature and mode of action of antilymphocytic antiserum. Proc Natl Acad Sci U S A (1966) 7.56
Studies on the immunological response to foreign tumor transplants in the mouse. I. The role of lymph node cells in conferring immunity by adoptive transfer. J Exp Med (1955) 4.89
Long-term survival of HeLa tumours in mice treated with antilymphocyte serum. Br J Cancer (1973) 1.69
The comparative effects of various steroids on lymphoid tissue of the rat. Cancer Res (1952) 1.08
Hormonal therapy in advanced renal cell carcinoma. Cancer (1971) 0.98
Vaccination against whooping-cough. Br Med J (1969) 3.15
Home therapy with recombinant interleukin-2 and interferon-alpha 2b in advanced human malignancies. Lancet (1990) 1.80
Long-term survival of HeLa tumours in mice treated with antilymphocyte serum. Br J Cancer (1973) 1.69
Does treatment with cimetidine extended beyond initial healing of duodenal ulcer reduce the subsequent relapse rate? Br Med J (Clin Res Ed) (1982) 1.69
Chromosome changes in human diploid-cell cultures infected with Mycoplasma. Nature (1965) 1.56
Prognostic factors for survival in patients with advanced renal cell carcinoma treated with recombinant interleukin-2. Ann Oncol (1992) 1.50
WHO collaborative studies on poliovirus type 3 strains isolated during the 1968 poliomyelitis epidemic in Poland. Bull World Health Organ (1972) 1.42
Low-dose subcutaneous recombinant interleukin-2 in advanced human malignancy: a phase II outpatient study. Mol Biother (1990) 1.37
Tumour nodule formation as an in vivo measure of the suppression of cellular immune response by antilymphocytic serum. Nature (1969) 1.36
The effect of sex hormones on peripheral immunity in patients with advanced breast cancer. Clin Oncol (1978) 1.26
The response to oral poliovaccine in persons aged 16-18 years. J Hyg (Lond) (1976) 1.22
Precautions against B virus infection. Br Med J (1966) 1.18
Correlation between clinical response to interleukin 2 therapy and sustained production of tumor necrosis factor. Cancer Res (1990) 1.14
Modification of amino-acid concentrations induced by mycoplasmas in cell culture medium. Nat New Biol (1971) 1.05
Subcutaneous growth of human tumours in mice. Nature (1973) 1.05
A comparison of the toxicity and efficacy of cisplatin and carboplatin in advanced ovarian cancer. The Swons Gynaecological Cancer Group. Acta Oncol (1989) 1.02
The British Standard for anti-rubella serum. J Biol Stand (1975) 1.01
Interleukin 2 therapy in cancer: identification of responders. Br J Cancer (1992) 1.00
Interleukin-2 and interferon-alpha in the treatment of patients with advanced non-small-cell lung cancer. J Immunother (1991) (1992) 0.96
Optimal conditions for the growth of malignant human and animal cell populations in immunosuppressed mice. Cancer Res (1975) 0.95
Growth of acute myeloid leukaemia as discrete subcutaneous tumours in immune-deprived mice. Br J Cancer (1977) 0.94
The impact of interleukin-2 on survival in renal cancer: a multivariate analysis. Cancer Biother (1993) 0.93
Karyological and morphological characteristics of human diploid cell strain WI-38 infected with mycoplasmas. Exp Cell Res (1969) 0.92
Safety of vaccines. Br Med Bull (1969) 0.92
Antibody response and reactions to aqueous influenza vaccine, simple emulsion vaccine and multiple emulsion vaccine. A report to the Medical Research Council Committee on influenza and other respiratory virus vaccines. J Hyg (Lond) (1969) 0.89
Systemic interleukin-2 therapy in children with progressive neuroblastoma after high dose chemotherapy and bone marrow transplantation. Bone Marrow Transplant (1989) 0.88
Continuous infusion of recombinant interleukin-2 with or without autologous lymphokine activated killer cells for the treatment of advanced renal cell carcinoma. Eur J Cancer (1992) 0.87
The effect of mycoplasma on the karyology of normal cells. Ann N Y Acad Sci (1967) 0.87
Functional and immunophenotypic modifications induced by interleukin-2 did not predict response to therapy in patients with renal cell carcinoma. J Biol Response Mod (1990) 0.87
An accelerated stability test procedure for lyophilized measles vaccines. J Biol Stand (1981) 0.85
Prognostic value of peripheral lymphocyte count in hormone therapy of advanced breast cancer. Br J Cancer (1976) 0.85
Sequential administration of recombinant human interleukin-2 and dacarbazine in metastatic melanoma: a multicenter phase II study. J Clin Oncol (1991) 0.84
Local activation of immune response in bladder cancer patients treated with intraarterial infusion of recombinant interleukin-2. Cancer Res (1991) 0.84
The treatment of metastatic renal cell carcinoma by continuous intravenous infusion of recombinant interleukin-2. Eur J Cancer (1994) 0.84
Metastatic growth of human tumour xenografts in thymectomised irradiated micr reconstituted with syngeneic bone marrow cells. Eur J Cancer (1975) 0.81
Treatment of leptomeningeal carcinomatosis with continuous intraventricular infusion of recombinant interleukin-2. Surg Neurol (1991) 0.81
The British reference preparation for influenza virus haemagglutinin. J Hyg (Lond) (1971) 0.81
Vaccination against communicable diseases. Am J Dis Child (1973) 0.81
A phase 2 trial of recombinant interleukin-2 and 5-fluorouracil in patients with metastatic colorectal carcinoma. Eur J Surg Oncol (1992) 0.81
Examination of cocksfoot pollen (Dactylis glomerata) extracts by skin prick test in man, RAST-based allergen assay and protein content. Dev Biol Stand (1975) 0.81
International collaborative studies on the pertussis vaccine potency assay. Part played by the challenge in the mouse-protection test. Bull World Health Organ (1971) 0.80
Growth of human tumours in immune-suppressed mice. Proc R Soc Med (1975) 0.80
Growth characteristics of a human bladder tumour subcutaneously implanted in immune deficient mice. Clin Oncol (1976) 0.80
Cell tumourigenicity detected by heterotransplantation into mice immunosuppressed with anti-lymphocytic serum. Prog Immunobiol Stand (1971) 0.80
Subcutaneous interleukin-2 and interferon-alpha 2b in patients with metastatic renal cell cancer: the German outpatient experience. Mol Biother (1990) 0.80
Cardioxane--ICRF-187 towards anticancer drug specificity through selective toxicity reduction. Cancer Treat Rev (1991) 0.80
Supplying cell cultures regularly to distant laboratories. Bull World Health Organ (1969) 0.80
Myocardial injury after interleukin-2 therapy. Lancet (1988) 0.80
Recombinant interleukin 2 for acute myeloid leukaemia in first complete remission: a pilot study. Leuk Res (1990) 0.79
Interleukin 2 therapy: current role in surgical oncological practice. Br J Surg (1993) 0.79
Intravenous interleukin-2 in patients over 65 with metastatic renal carcinoma. Br J Cancer (1992) 0.79
The growth of tumour xenografts in thymectomized high dose irradiated mice reconstituted with syngeneic bone marrow cells incubated with anti-thymocyte serum. Br J Cancer (1976) 0.79
Licensed vaccines. Rev Infect Dis (1985) 0.78
Control of influenza vaccine, with special reference to experience in the United Kingdom. Bull World Health Organ (1969) 0.78
Intravesical therapy of superficial bladder transitional cell carcinoma with tumor necrosis factor-alpha: preliminary report of a phase I-II study. Eur Urol (1992) 0.78
Standards of karyology for human diploid cells. J Biol Stand (1974) 0.78
A phase II study of sequential recombinant interleukin-2 followed by dacarbazine in metastatic melanoma. Eur J Cancer (1992) 0.78
Phase I trial of recombinant interleukin-2 followed by recombinant tumor necrosis factor in patients with metastatic cancer. J Immunother (1991) (1992) 0.78
Neoplastic macrophages grown from human leukaemic monocytes. J Pathol (1977) 0.77
A phase III study of recombinant interleukin-2, 5-fluorouracil and leucovorin versus 5-fluorouracil and leucovorin in patients with unresectable or metastatic colorectal carcinoma. Eur J Cancer (1995) 0.77
A phase-II trial of recombinant interleukin-2 and 5-FU chemotherapy in patients with metastatic colorectal carcinoma. Cancer Treat Rev (1989) 0.77
Recombinant interleukin-2 treatment in patients with metastatic colorectal cancer: effect on natural cytotoxicity. Cancer Immunol Immunother (1992) 0.77
Effect of prolonged subcutaneous administration of interleukin-2 on the circadian rhythms of cortisol and beta-endorphin in advanced small cell lung cancer patients. Tumori (1991) 0.77
The development of neutralizing antibodies in a patient receiving subcutaneous recombinant and natural interleukin-2. Cancer (1991) 0.76
Measurement of antitumour activity of actinomycin D. Nature (1971) 0.76
Experience in the United Kingdom with oil adjuvant influenza vaccines. Ann Allergy (1972) 0.76
Creatine kinase isoenzymes in serum of patients with cancer of various organs. Clin Chem (1978) 0.76
Persistent augmentation of natural-killer- and T-cell-mediated cytotoxicity in peripheral blood mononuclear cells pulsed in vitro with high-dose recombinant interleukin-2 prior to culturing with a low maintenance dose. Cancer Immunol Immunother (1994) 0.76
A multicenter trial of interleukin-2 and low-dose cyclophosphamide in highly chemotherapy-resistant malignancies. Cancer Treat Rev (1989) 0.76
Letter: Hormone exposure and lymphocytic impairment. JAMA (1975) 0.76
A phase II study of the platinum analogues JM8 and JM9 in malignant pleural mesothelioma. Cancer Chemother Pharmacol (1986) 0.75
A phase-III study of recombinant interleukin 2 and 5-fluorouracil chemotherapy in patients with metastatic colorectal cancer. Br J Cancer (1993) 0.75
Variation of killing power of human sera against Bordetella pertussis. Clin Exp Immunol (1969) 0.75
Standardization of diagnostic materials. 5. Tissue culture media and reagents. Bull World Health Organ (1973) 0.75
Factors influencing immunization against poliomyelitis. Proc R Soc Med (1969) 0.75
Letter: Human tumour xenografts. Br Med J (1975) 0.75
Hormone receptors and human breast cancer. Br Med J (1980) 0.75
Comparison of virus titre results obtained in four different laboratories using different virus assay techniques. Boll Ist Sieroter Milan (1997) 0.75
The need for a standardised cell substrate for virus vaccine production. Jpn J Med Sci Biol (1971) 0.75
Virus vaccines: introduction. Lab Pract (1970) 0.75
Leslie Frank Hewitt; 20 May 1901-14 March 1967. J Pathol Bacteriol (1968) 0.75
Cell cultures. Science (1967) 0.75
The use of standardized cell substrates as an alternative to primary animal tissue for vaccine production. Proc R Soc Med (1970) 0.75
The need for a standardised cell substrate for virus vaccine production. Ann Ist Super Sanita (1969) 0.75
Vaccines produced in diploid cell lines--discussion. Natl Cancer Inst Monogr (1968) 0.75
The laboratory control of vaccines. Sci Basis Med Annu Rev (1968) 0.75
A review of recent studies with rubella vaccines. Public Health (1967) 0.75
m-AMSA and VP-16 combinations in the treatment of acute myeloid leukemia. Br J Haematol (1987) 0.75
F. General conclusions on safety of viral vaccines. Prog Immunobiol Stand (1967) 0.75
The laboratory control of viral vaccines. Prog Immunobiol Stand (1967) 0.75
Virus vaccines--dead or alive? Sci Basis Med Annu Rev (1965) 0.75
Problems in the control of certain biological products. WHO Chron (1969) 0.75